Atelerix's innovative technology overcomes the barriers and limitations of the current need for cryo-shipping. The company, backed by the Northern Accelerator, use a patented process of encapsulating the cells and tissues in a natural alginate hydrogel made from seaweed. The cells and tissues can be recovered when needed by the addition of a gentle, cell-friendly buffer.

The method is practical and adaptable, opening up the market for the supply of cells and assays in a ready-to-use format, allowing cell suppliers to scale up their businesses, increase the range of assays available to consumers and improve access to stem cell therapy. Benefits include predictability and reliability in drug discovery models and for cells used as therapies, the opportunity for customers to use cells and assays immediately on arrival and removing the need for cryopreservation, or the alternative need for cytotoxic or animal-derived supplements.

In May 2019 Atelerix announced they'd closed a second round of funding of £700,000 to accelerate development of its products to market, and in February 2024 the company completed a further funding round of £500,000.

Image: Atelerix CSO Steve Swioklo in the Atelerix lab